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Abstract
Objectives: Heart failure [HF] hospital readmissions are a continued challenge in the care of HF patients, which
contribute substantially to the high costs of the disease and high mortality rate in lower to middle income country. We
implemented a quality improvement project to improve patient outcomes and resource utilization.
Methods: This study was a prospective cohort design with a historical comparison group. It was conducted to assess the
difference in 30-day readmissions and mortality and to assess compliance rate with HF guideline between the historical
pre-intervention audit 1 cohort and prospective post-intervention audit 2 cohorts. Audit 1 cohort were recruited from
January to February 2019, whereas, audit 2 cohort which received the bundled intervention program were recruited from
July to December 2019. Clinical outcomes were compared between cohorts using 30-day readmissions and mortality.
Results: A total of 50 and 164 patients were included in audit 1 and audit 2 cohort, respectively. Patients in the audit 2
cohort were younger [63.0 ± 14.5 in audit 1 vs 56.5 ± 12.7 in audit 2, p ¼ 0.003] and majority were male [50.0% in audit 1
vs 72.0% in audit2, p ¼ 0.004]. Thirty-day readmissions were signiﬁcantly different [36.0% audit 1 vs. 22.0% audit 2,
p ¼ 0.045], but the mortality rates were similar [4.0%% audit 1 vs. 5.5% audit 2, p ¼ 0.677] between two cohorts.
Conclusion: A signiﬁcant decrease in 30-day readmissions was observed in the post-intervention audit 2 cohort in our
setting. Further study in larger population and prolong study follow-up is warranted.
Keywords: Congestive heart failure, Left ventricular failure, Heart failure

1. Background

H

eart failure [HF] poses signiﬁcant health and
economic challenges. In Malaysia, the disease is an essential cause of hospitalization accounting for 6.7%e9.0% of all acute medical
admissions [1,2]. The cost of managing HF is high.
In 2012, the estimated overall HF economic cost
was $USD108 billion [MYR 462 billion] per annum
globally and $USD 194 million [MYR 830 million]
for Malaysia [3]. A diagnosis of HF in Asia paciﬁc

region is expensive and disastrous to the patients,
his family members, society and nation [4].
HF patients are prone to repetitive hospital admissions. To make the matter worse, the pool of
potential HF patients is estimated to be expanded
due to aging population and by the successes of
treating other ischemic heart diseases [5]. Readmission measures are estimates of unplanned
readmission for any reason to an acute care hospital
in the 30 days after discharge from a hospitalization.
High hospital readmission rate is used in certain
government as indicators of poor care or missed
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opportunities to better coordinate care [6]. In the
western countries, rates of HF 30-day readmissions
range between 19.6% and 24.7% [5,7], while in Asian
countries, the rate is between 3.0% and 15.0% and
for Malaysia, 30-days HF readmissions is 8.0% [8]. It
is of note that readmission range between western
and Asian countries are not head to head trial and
thus should not be compared directly.
There are many factors accounted for early readmission following HF hospitalization and these were
not easily categorized into mutually exclusive reasons. Some of the common cause such as development of new condition or worsening of the
underlying chronic diseases [9], was not preventable.
On the other hand, some of the factors deemed
avoidable include: potentially premature discharge
from index admission, inadequate coordinating care
transition and discharge planning, underuse of heart
failure medications, insufﬁcient patient education
and follow-up [10,11]. Increased attention to these
factors is important in optimizing HF management.
Multidisciplinary team approach which strengthens
the communication between healthcare teams, prompt
outpatient follow-up, hospital quality-improvement
programs, consistency in implementing evidencebased practice [11e17] were well-documented in
reducing HF readmissions. Notably, many of these
strategies were translated from interventions tested in
controlled environments and complemented with
huge manpower and resources. It is thus challenging
to implement it in daily practice and scientiﬁc publication may not reﬂect all variables in the real-world
setting. Determining factors which may contribute to
readmission in own facilities are therefore important
and audit is a useful tool in doing so.
This quality improvement project aims to improve
patient outcomes and resource utilization. The
speciﬁc objectives were: To assess the difference in
30-day readmissions and mortality between the
historical pre-intervention audit 1 cohort and prospective post-intervention audit 2 cohorts, and to
assess compliance rate with HF guideline.

2. Materials and methods
2.1. Study design
This study was a prospective cohort design with a
historical comparison group. Hypothesis was made
that there was no difference in 30-day readmissions
between the 2 audit cohorts. A BIP was implemented
as part of the HF usual care from April 2019 onward
to address issues arise in audit 1. A six months
follow-up audit [Audit 2] was then carried out from
July to December 2019. A case report form was used

Abbreviation list
ACEI
ACS
ADHF
ARB
ARNI
BIP
CABG
DM
HF
IHD
LVEF
MRA
MYR
PCI
RAAS
USD

Angiotensin-converting enzyme inhibitors
Acute coronary syndrome
Acute decompensated heart failure
Angiotensin receptor blockers
Angiotensin neprilysin inhibitors
Bundled intervention program
Coronary artery bypass graft
Diabetes mellitus
Heart failure
Ischaemic heart disease
Left ventricular ejection fraction
Mineralocorticoid receptor antagonists
Malaysian ringgit
Percutaneous coronary intervention
Renin angiotensin aldosterone system
U.S. dollar

to facilitate data collection. The data collected from
the case notes include: baseline characteristics, comorbidities, aetiologies of ADHF and aetiologies of
readmissions. The design of the work has been
approved by Ministry of Health Malaysia and waiver
of informed consent obtained from Medical
Research Ethics Committee [MREC] [NMRR-183591-44996]. Individual consent for participation was
not required as all patients received the BIP as part
of their usual care. The study adhered to strict information governance and security protocols.
2.2. Study setting and study population
All ADHF patients admitted to cardiology ward
Hospital Serdang Malaysia, a tertiary referral cardiology centre was included in the audit, irrespective of their underlying aetiology. These
patients were identiﬁed by the conﬁrmed primary
diagnosis of ADHF by the auditors. Exclusion
criteria were patients below 18-years old, patients
who passed away or required inpatient coronary
artery bypass graft [CABG] during index admission.
CABG patients were excluded because they were
transferred to cardiothoracic ward and the HF care
will be managed by a different team. The index
admissions were deﬁned as the ﬁrst admission
carrying ADHF as a primary diagnosis for a patient
from 1st January 2019 to 31st December 2019. ADHF
readmissions for the same patient during the audit
period, only the ﬁrst admission for the year was
included among index admissions.
2.3. Outcomes
The clinical outcomes of ADHF patients were
measured using 30-day readmissions and mortality.

30-day all-cause readmissions were deﬁned as an
admission to a hospital within 30 days of discharge
from the same or another hospital. Lengths of initial
hospitalizations were calculated and 30-day allcause readmissions were examined via clinical
notes. The prespeciﬁed period of readmission was
within 30 days of discharge with at least 24 h’ unplanned stay in hospital. The aetiologies of 30-day
readmissions were also recorded.
2.4. Description of audit key indicators
Audit key indicators were adopted and adapted
from 2016 ESC Guidelines for the diagnosis and
treatment of acute and chronic heart failure [18],
2014 Management of Heart Failure 3rd Edition
Clinical Practice Guideline 2014 [19] and Target: HF
Strategies and Clinical Tools [20]. A total of 7 audit
key indicators were established in audit 1. The key
indicators include provide immediate care, review
by specialists, initiate speciﬁc treatment, obtained
baseline echocardiography, initiate and up-titrate
HF key medications, device therapy referral if
indicated and clinic provider follow-up. The
compliance with HF guidelines was determined via
compliance with the audit key indicators.
2.5. Bundle intervention program [BIP]
A BIP was implemented to address issues arise in
baseline audit. This included a multidisciplinary
ward round lead by a cardiologist, inclusion of
treatment checklist in patients’ bed head ticket,
inpatient cardiac rehabilitation and dieticians counselling session, medication reconciliation, 30 min
standardized patient education and HF management
counselling by pharmacist. The standardized education content provided by the multidisciplinary
team consist of instructions on medications, daily
weight monitoring, diet and sodium intake, exercise,
a list of symptoms for patients to report if they
experienced; and smoking cessation. Family members and caregivers were included in the educational
sessions when available and verbal consent obtained
on willing to participate. The standardized educational session was to reduce variances in information
provided to HF patients and families, with staff
consistently delivering the same message across the
continuum of care.
2.6. Statistical analysis
Statistical analysis was performed using IBM
Corp. Released 2017. IBM SPSS Statistics for Windows, Version 25.0. Armonk, NY: IBM Corp.
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Descriptive statistics were used for demographic
characteristics, determining readmissions and
mortality rate. The characteristics of patient cohorts
in audit 1 and audit 2 was compared using Chisquare and Fisher's Exact test for categorical variables and Student's t-test for continuous variables.
An independent sample Mann-Whitney U test was
utilized when comparing non-parametric data such
as total length of stay and left ventricular ejection
fraction [LVEF], as these data violated the assumptions of parametric tests. Further analyses were
repeated by excluding patients undergoing PCI. A
signiﬁcance level of P < 0.05 was considered statistically signiﬁcant for all tests.

3. Results
3.1. Baseline characteristics
During the entire audit period, a total of 265 patients were admitted due to ADHF, 214 were eligible
for recruitment. Fifty and 164 patients were included
in audit 1 and audit 2 cohort respectively. Patients in
audit 2 were younger [63.0 ± 14.5 years in audit 1,
56.5 ± 12.7 years in audit 2; p ¼ 0.003] and majority
were male [50% in audit 1, 72.0% in audit 2;
p ¼ 0.004] [Table 1]. There was no statistically signiﬁcant difference in length of hospital stay and
LVEF between audit 1 and audit 2 cohorts. Similar
baseline characteristics pattern was observed between 2 cohorts before and after PCI patients were
excluded [Table 1].
3.2. Audit key indicators
Seven audit key indicators were monitored during
audit 1. Audit key indicators such as providing immediate care, review by specialist achieved 100% in
all patients in both audit cycle. LVEF was assessed in
58.0% of all audit 1 patients while in the hospital or
they had an assessment before hospitalization. This
subsequently signiﬁcantly increased to 81.6% in
audit 2, p ¼ 0.001. There are also more patients with
optimized blood pressure at discharge in audit 2
[60.0% in audit 1 versus 79.9% in audit 2; p ¼ 0.006].
In comparison to the audit 1 cohort, the proportion
of HF patients in audit 2 cohort prescribed with a
beta-blocker [58.0% in audit 1 versus 78.0% in audit
2, p ¼ 0.006] increased signiﬁcantly. Throughout the
audit period, several measures were added to reduce
readmissions. Of note, the proportion of patients
with a documented reason of RAAS [32.1% in audit 1
vs 67.5% in audit 2, p ¼ 0.002] and MRA ineligibility
[18.2% in audit 1 vs 51.6% in audit 2, p ¼ 0.001]
increased signiﬁcantly respectively [Table 2].
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Table 1. Baseline characteristics.
Variable

Age, years
Male
Median LVEF, % [IQR]
Median length of stay, days
[IQR]
Comorbidities
IHD and ACS events
Arrhythmias
Past Stroke/TIA events
Diabetes mellitus
Hyperlipidaemia
Metabolic derangements [ex:
thyroid disease, Addison
disease]
Immune mediated &
inﬂammatory damage
[autoimmune disease]
Inﬁltration [cancer,
malignancy, amyloidosis,
sarcoidosis, pompe disease,
connective tissue disorders]
Peripartum cardiomyopathy
Asthma/COPD
CKD/ESRF
Hypertension
Genetic abnormalities
Valvular heart disease
Others
Aetiology of ADHF
Ischemic, ACS events
Non-compliant to ﬂuid
Non-compliant to medication
Uncontrolled hypertension
Arrhythmia
Superimposed infection
Thyroid disease
Worsening renal disease
Valvular heart disease
Other factors [etc. nonischemic DCM]
Mixed factors
ADHF factors not
documented

All Patients [N ¼ 214]

Patients with PCI Excluded [N ¼ 196]

Audit 1 [n ¼ 50]

Audit 2 [n ¼ 164]

p-value

Audit 1 [n ¼ 50]

Audit 2 [n ¼ 146]

p-value

63.0 ± 14.5
25 [50.0]
39 [23.5]
6 [7]

56.6 ± 12.7
118 [72.0]
33.5 [20.0]
7 [8]

0.003
0.004
0.069
0.312

63.0 ± 14.5
25 [50.0]
39 [23.5]
6 [7]

57.5 ± 12.5
104 [71.2]
30.6 [21.0]
7 [7]

0.01
0.006
0.098
0.332

23 [46.0]
10 [20.0]
6 [12.0]
30 [60.0]
23 [46.0]
5 [10.0]

98 [59.8]
23 [14.0]
11 [6.7]
103 [62.8]
39 [23.8]
6 [3.7]

0.086
0.370
0.238
0.741
0.003
0.134

23 [46.0]
10 [20.0]
6 [12.0]
30 [60.0]
23 [46.0]
5 [10.0]

90 [61.6]
20 [13.7]
11 [7.5]
98 [ 67.1]
35 [24.0]
6 [4.1]

0.053
0.285
0.333
0.361
0.003
0.118

0 [0.0]

8 [4.9]

0.203

0 [0.0]

8 [5.5]

0.091

0 [0.0]

2 [1.2]

1.000

0 [0.0]

2 [1.4]

1.000

0 [0.0]
8 [16.0]
11 [22.0]
36 [72.0]
0 [0.0]
4 [8.0]
10 [20.0]

0 [0.0]
14 [8.5]
44 [26.8]
110 [67.1]
0 [0.0]
10 [6.1]
58 [35.4]

e
0.180
0.581
0.604
e
0.744
0.056

0 [0.0]
8 [16.0]
11 [22.0]
36 [72.0]
0 [0.0]
4 [8.0]
10 [20.0]

0 [0.0]
12 [8.2]
42 [28.8]
104 [71.2]
0 [0.0]
9 [6.2]
55 [37.3]

e
0.117
0.352
0.917
e
0.743
0.022

2
0
0
2
2
7
0
0
2
0

[4.0]
[0.0]
[0.0]
[4.0]
[4.0]
[14.0]
[0.0]
[0.0]
[4.0]
[0.0]

55 [33.5]
27 [16.5]
1 [0.6]
4 [2.4]
6 [3.7]
11 [6.7]
0 [0.0]
10 [6.1]
2 [1.2]
15 [9.1]

0.001
0.001
1.000
0.626
1.000
0.142
e
0.121
0.233
0.025

2
0
0
2
2
7
0
0
2
0

[4.0]
[0.0]
[0.0]
[4.0]
[4.0]
[14.0]
[0.0]
[0.0]
[4.0]
[0.0]

47 [32.2]
27 [18.5]
1 [0.7]
3 [2.1]
6 [4.1]
11 [7.5]
0 [0.0]
9 [6.2]
2 [1.4]
13 [8.9]

0.001
0.001
1.000
0.603
1.000
0.172
e
0.115
0.269
0.042

34 [68.0]
1 [2.0]

33 [20.1]
10 [6.1]

0.001
0.464

34 [68.0]
1 [2.0]

29 [19.9]
8 [5.5]

0.001
0.452

Data are n [%] unless stated otherwise. Data expressed as mean ± standard deviation for continuous variables. ACS, acute coronary
syndrome; ADHF, acute decompensated heart failure; CKD: chronic kidney disease; COPD: chronic obstructive pulmonary disease;
DCM, dilated cardiomyopathy; DM: diabetes mellitus; LVEF: left ventricular ejection fraction; TIA: transient ischemic attack.

3.3. Thirty-day readmissions and mortality
The study showed that 30-day readmissions were
signiﬁcantly different [36.0% audit 1 cohort vs.
22.0% for the audit 2 cohort respectively, p ¼ 0.045]
[Table 3a]. However, when further analyses
repeated by excluding patients undergoing PCI,
these results were attenuated [Table 3b]. The mortality rates were similar for both cohorts before and
after excluding patients undergone PCI [Table 3a,
b]. Among the aetiologies of readmission, noncompliant to ﬂuid was common in audit 1, and was

signiﬁcantly lower in audit 2, [45.0%in audit 1 vs
0.0% in audit 2; p ¼ 0.001, Table 4]. Readmission
aetiologies were not signiﬁcantly different for all
other causes [Table 4].

4. Discussion
This quality improvement project improved patients’ outcomes and resource utilization in our
centre. Thirty-day readmissions were both numerically and statistically reduced in the post-intervention audit 2 cohort in our setting treated with BIP.

Table 2. Audit key indicators.
Audit Standard

Variables

Audit 1 [n ¼ 50]

Audit 2 [n ¼ 164]

p-value

Provide immediate care
Review by specialists
Initiate Speciﬁc Treatment

Provide immediate care
Review by specialists
To start appropriate therapy to target &
control symptoms
Optimize BP
Availability of echocardiography within
the same year
Initiate RAAS
Initiate Beta Blocker
Initiate MRA
Initiate Ivabradine
Patients with documented reason for
RAAS ineligibility
Patients with documented reason for
Beta Blocker ineligibility
Patients with documented reason for
MRA ineligibility
Patients with documented reason for
Ivabradine ineligibility
Device Therapy Referral
HF Management Counselling by
Pharmacist
Cardiac Rehabilitation Counselling
During Admission
Dietitian Counselling During
Admission
Cardiologist follow-up only
Primary care follow-up only
Both cardiologist and primary care
follow-up
Follow-up not mentioned
Nurses Follow-Up Phone Calls

50 [100.0]
50 [100.0]
50 [100.0]

164 [100]
164 [100]
164 [100]

1.000
1.000
1.000

30 [60.0]
29 [58.0]

131 [79.9]
133 [81.6]

0.006
0.001

22 [44.0]
29 [58.0]
17 [34.0]
1 [2.0]
n ¼ 28
9 [32.1]
n ¼ 21
11 [52.4]
n ¼ 33
6 [18.2]
n ¼ 49
0 [0.0]
0 [0.0]
0 [0.0]

84 [51.2]
128 [78.0]
71 [43.3]
12 [7.3]
n ¼ 80
54 [67.5]
n ¼ 36
18 [50.0]
n ¼ 93
48 [51.6]
n ¼ 152
15 [9.9]
8 [4.9]
144 [87.8]

0.421
0.006
0.256
0.308
0.002

0.203
0.001

0 [0.0]

68 [41.5]

0.001

0 [0.0]

72 [43.9]

0.001

50 [100.0]
0 [0.0]
0 [0.0]

100 [61.0]
4 [2.4]
50 [30.5]

0.001
0.575
0.001

0 [0.0]
0 [0.0]

10 [6.1]
78 [47.6]

0.121
0.001

Perform
echocardiography
Initiate and up-titrate HF
key medications

Device therapy referral
HF counselling

Follow ups/referrals

Telephone follow up

1.000
0.001
0.024

Data are n [%] unless stated otherwise.

Table 3a. 30-day Readmissions and Mortality (All patients).
Clinical Outcomes

Table 4. 30-day readmissions and mortality aetiologies.

Audit 1 [n ¼ 50] Audit 2 [n ¼ 164] p-value

30-day Readmissions 18 [36.0]
30-day Mortality
2 [4.0]

36 [22.0]
9 [5.5]

0.045
0.677

Data are n [%] unless stated otherwise.

Table 3b. 30-day Readmissions and Mortality of HF patients on medical
treatment [repeated analysis by excluding patients with PCI].
Clinical Outcomes

Audit 1 [n ¼ 50] Audit 2 [n ¼ 146] p-value

30-day Readmissions 18 [36.0]
30-day Mortality
2 [4.0]

33 [22.6]
9 [6.2]

0.062
0.733

Data are n [%] unless stated otherwise.

Our patients were relatively younger, co-morbidities were generally common, compared to other
countries [21], and more likely to battle with this
chronic disease longer. Thus, reducing readmission
is utmost important.
In our study, 30-day readmissions were reduced
to 22.0% in audit 2 cohort; where other studies show
a substantial variation in 30-day readmissions
ranging between 6% and 23% [17,22e24]. The variation of results was due to the different inclusion

Variable

Audit 1
[n ¼ 20]

Audit 2
[n ¼ 45]

p-value

Ischemic, ACS events
Non-compliant to medication
Non-compliant to ﬂuid
Uncontrolled hypertension
Arrhythmia
Superimposed infection
Thyroid disease
Worsening renal disease
Valvular heart disease
Other factors [etc. non-ischemic
DCM, over-warfarin]
Mixed factors
ADHF factors not documented

3
0
9
0
0
4
1
1
0
0

11 [24.4]
8 [17.8]
0 [0.0]
0 [0.0]
2 [4.4]
2 [4.4]
0 [0.0]
2 [4.4]
0 [0.0]
3 [6.7]

0.521
0.051
0.001
e
1.000
0.067
0.308
1.000
e
0.547

4 [8.9]
9 [20.0]

0.303
0.480

[15.0]
[0.0]
[45.0]
[0.0]
[0.0]
[20.0]
[5.0]
[5.0]
[0.0]
[0.0]

0 [0.0]
2 [10.0]

Data are n [%] unless stated otherwise.

and exclusion criteria. We found that in one study
which obtained good reduction in 30-day readmissions, patients with concomitant illnesses which
could inﬂuence short term prognosis such as
concomitant unstable angina or acute myocardial
infarction were excluded [22]. In the additional analyses, the 30-day readmissions were attenuated but
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the mortality rate was similar after patients underwent PCI were excluded. We postulated that mortality beneﬁt may be signiﬁcant if follow up duration
was prolonged. This is showed in a Korean acute HF
registry which recruited Asia patients with acute
ischemic HF; where the rate of death from any cause
was lower over a period of 4 years [32].
The decrease in hospital readmissions made
additional patient beds available where more patients could be treated. Our program was unique
where an existing multidisciplinary service was
consolidated and utilized; rather than creating a
new resource-intensive service. Combining strength
from various healthcare personnel is essential and
this was the highlight in a meta-analysis where
isolated intervention has small effects and did not
associate with a reduced 30-day readmissions while
bundled interventions which postulated to change
the value in cultural or organization factors have an
additive effect [25].
Despite this study showed that 30-day readmissions
were reduced in audit 2 cohort, treatment gap and low
compliance rate with evidence-based recommendations for ADHF patients among practitioner still exist
for a considerable large proportion of patients. This
include the availability of echocardiography, initiation of HF key medications, referral to cardiac rehabilitation and nurses phone calls follow up.
Echocardiography used less often in audit 1 cohort,
highlighting potential opportunities to improve outcomes. Despite the rate increased to 79.9% after BIP
was introduced, this still leaves 20.1% of patients not
accessing echocardiography in hospital and having
no record of a recent echocardiography within the last
six months. The use of handheld echocardiography
and brain natriuretic peptides [BNP] level was shown
to reduce the needs of a time-consuming full scan on
every HF patient before discharge. Both methods are
also effective to optimize intravascular volume status.
Thus these interventions may be considered in future
management of HF patients [22].
A lower than recommended rate of prescribing
HF key medications before patients discharge was
profound when compared to other Asia countries
[4,8]. The prescription of beta-blockers improved
markedly after the introduction of BIP. Still, the
prescribing rate for Renin angiotensin aldosterone
system [RAAS] blockers, mineralocorticoid receptor
antagonists [MRA] and ivabradine were not significantly increased. Our prescribing rate for RAAS
blockers, beta-blockers, MRA after introduction of
BIP program was 51.2%, 78.0%, 43.3%, respectively,
versus 83.0%, 87.0%, 53.0% in 2016e2017 national
heart failure audit in UK [26] and 63.0%, 41.0% and
31.0% in Asia paciﬁc registry [4].

In this study, patients with documented reason for
ineligibility increased substantially for both agents
after introduction of BIP program. This may suggest
the increase of awareness of prescribing key modifying agents. With new evidence involving the introduction of ARNI [27]; and ivabradine pre-discharge
without increasing adverse events [28]; achieving
higher prescription rates for all these agents during
discharge and titration to the maximum tolerated or
target dose should be a goal and an area for targeting
better practice in the next audit.
BIP programme increased education through
infographic and direct counselling to ensure understanding of HF diagnosis, symptom recognition,
adherence of medicines, sodium and ﬂuid restriction, weight monitoring, physical activity level and
exercise plan. This was done by medical ofﬁcers,
pharmacists, dietician and cardiac rehabilitation
physicians. The previous study demonstrated that
patients who were not able to recognize HF symptoms delayed for days before reacting [29]. Thus,
education is essential and method to increase the
counselling rate should be conducted.
This audit cohort captures data on the guidelinebased management of HF in the cardiology ward in
a single tertiary referral centre, which requires
interpretation within certain limitations as multimorbid case-mix our centre attracts may not be
entirely generalisable. This study is subject to
inherent selection bias as patients who underwent
CABG were excluded but patients who underwent
PCI were not. In order to overcome this inherent
selection bias, the additional analyses were done by
excluding patients undergoing PCI.

5. Conclusion
This quality improvement project provides an
overview of the current practice. The study
demonstrated that increased adherence to guideline-directed HF management could be achieved
through clinical audit and agreed intervention program. Project lessons learned suggest that all parties
should be actively involved in changing practices at
the facilities, and greater collaboration between the
multidisciplinary team with consistent mentoring
by experienced clinicians is essential to ensure
sustainment of the practice change.
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